Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial

Abstract

OBJECTIVE To demonstrate the performance and safety of a bihormonal (insulin and glucagon) artificial pancreas (AP) in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS In this outpatient, randomized, crossover trial, 2-week fully closed loop glucose control (AP therapy) was compared with 2-week open loop control (patient’s normal insulin pump therapy with a glucose sensor if they had one). RESULTS A total of 23 patients were included in the analysis. Time in range (70–180 mg/dL [3.9–10 mmol/L]) was significantly higher during closed loop (median 86.6% of time [interquartile range 84.9–88.5]) compared with open loop (53.9% [49.7–67.2]; P < 0.0001). CONCLUSIONS Compared with insulin pump therapy, the bihormonal AP provided superior glucose control, without meal or exercise announcements, and was safe in adults with type 1 diabetes.